Skip to main content
. Author manuscript; available in PMC: 2023 Aug 25.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2010 Nov 12;20(1):36–44. doi: 10.1002/pds.2029

Figure 3.

Figure 3.

Forest plots of difference in each lipid level compared to the average metformin user for each OAD exposure and with the use of statin and non-statin lipid lowering medication use. *The intercept represents an average white male metformin user without cardiovascular disease, not using any lipid lowering medication, who entered the cohort in 2000 and adjusted for the average baseline HbA1c, total cholesterol, HDL, and triglycerides